Sera Prognostics (NASDAQ:SERA) Rating Lowered to Sell at Wall Street Zen

Sera Prognostics (NASDAQ:SERA) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Sera Prognostics Stock Down 4.6%

Shares of SERA stock opened at $2.48 on Friday. The firm has a 50 day moving average price of $2.42 and a two-hundred day moving average price of $3.20. The company has a market capitalization of $93.42 million, a PE ratio of -2.92 and a beta of 0.99. Sera Prognostics has a 12-month low of $1.37 and a 12-month high of $9.13.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.05. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.05 million. Sera Prognostics had a negative net margin of 30,306.48% and a negative return on equity of 45.86%. As a group, research analysts expect that Sera Prognostics will post -0.96 EPS for the current year.

Insider Transactions at Sera Prognostics

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 23,042 shares of the firm’s stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $1.43, for a total transaction of $32,950.06. Following the completion of the sale, the chief executive officer directly owned 844,209 shares in the company, valued at $1,207,218.87. This trade represents a 2.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 38,014 shares of company stock worth $55,268 in the last three months. Company insiders own 15.80% of the company’s stock.

Institutional Investors Weigh In On Sera Prognostics

Hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets acquired a new stake in Sera Prognostics during the fourth quarter worth approximately $28,000. Abel Hall LLC acquired a new stake in shares of Sera Prognostics in the second quarter valued at approximately $31,000. Wagner Wealth Management LLC acquired a new stake in shares of Sera Prognostics in the second quarter valued at approximately $34,000. XTX Topco Ltd acquired a new stake in shares of Sera Prognostics in the first quarter valued at approximately $39,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in shares of Sera Prognostics in the fourth quarter valued at approximately $93,000. 54.64% of the stock is currently owned by institutional investors and hedge funds.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.